Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, genetic testing confirmed the diagnosis of Androgen insensitivity syndrome in most CAIS patients in Tunisia and identified two previously unreported mutations in the androgen receptor gene.

This study identified a new clinical variant of adult adrenomyeloneuropathy characterized by hypoplasia and agenesis of the corpus callosum, associated with a novel ABCD1 gene mutation.

In this study, machine learning-based computer-aided diagnosis significantly improved accuracy in diagnosing alopecia areata compared to traditional visual methods, achieving up to 91.9% accuracy using different classifiers like CNN, SVM, and random forest models.

This study reports that hypomorphic alleles of the Ass1 gene in mice resemble human CTLN1, providing a potential model for preclinical studies and indicating that standard treatments for CTLN1 can rescue phenotypes.

This study identified four novel and one recurrent mutation in the AIRE gene among Arab families with APS1, suggesting these contribute to the disorder.

IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This study found that Aire‒/‒ mice spontaneously developed persistent AA-like lesions, highlighting a potential role for AIRE in hair follicle biology and pathogenesis of alopecia areata.

This report highlights a case of adrenoleukodystrophy, a rare disease, diagnosed in a young boy with neuropsychiatric symptoms and Addison's disease, stressing the importance of early diagnosis and genetic counseling.

This study found that intramuscular triamcinolone acetonide may be an effective and safe treatment option for managing refractory alopecia areata, showing a 63% response rate in patients and hair regrowth negatively correlated with initial scalp involvement.

This study found that anti-Müllerian hormone (AMH) is a valuable primary variable for classifying functional androgenization, especially in distinguishing ovarian-related groups, and supports the novel stratification system.

This study used a multi-layer in silico framework to evaluate Korean herbal compounds for androgenetic alopecia, identifying Biochanin A, Saponin Re, and Emodin as potential topical candidates with distinct safety and affinity profiles, although these findings remain purely computational without experimental validation.

This study found that ischemia-modified albumin (IMA) may be a promising biomarker of oxidative stress in patients with alopecia areata, offering better potential compared to other oxidative stress markers.

This review explored treatment options for alopecia areata in the military health care system, evaluating the pathogenesis and impact of the condition as well as the efficacy and safety of FDA-approved JAK inhibitors, baricitinib and ritlecitinib.

This study evaluated the use of AI software SwissADME to compare Minoxidil and Sildenafil for alopecia treatment, finding Minoxidil to be more effective and safer, while highlighting limited potential for Sildenafil and emphasizing AI's role in optimizing drug development.

This study reviews AI's role in aesthetic medicine, noting it enhances diagnostic accuracy and personalized treatment planning, but faces challenges like ethical concerns, algorithmic biases, and regulatory issues that need addressing for successful integration.

This study explores how Astragaloside A from traditional Chinese medicine may combat lung adenocarcinoma by regulating key signaling molecules like STAT3 and AKT, using techniques such as network pharmacology and molecular docking to understand its mechanisms in cellular models.

In this study, researchers described protocols using C3H/HeJ mice to reliably induce alopecia areata through full-thickness skin grafts or adoptive transfer of cultured lymphoid cells, offering valuable models for studying the disease and testing new drug therapies.

This consensus statement from Saudi Arabia outlines evidence- and experience-based recommendations for diagnosing and managing alopecia areata, focusing on severity assessment, prognostic indicators, and therapeutic options, with special attention to pediatric patients and uncommon cases.

This article discusses a potential link between adipocyte-myofibroblast transition and androgenetic alopecia, suggesting AMT may play a role in fibrosis associated with the condition but presents no new results.

This study found that higher Dietary Inflammatory Index scores were significantly associated with an increase in both the occurrence and severity of alopecia areata.

In this study, the researchers reported that ischemia-modified albumin and IMA/albumin levels may not effectively predict disease severity in patients with alopecia areata.

This article reviews antibody drug conjugates for cancer treatment, describing their mechanism, recent approvals, and ongoing research efforts, but reports no new clinical results.

This study review reports that alopecia areata is often associated with autoimmune thyroid diseases like Hashimoto thyroiditis, suggesting targeted thyroid screening based on symptoms and risk factors may improve detection while minimizing unnecessary tests.

Arg1+ macrophages may play a role in Alopecia Areata, offering new treatment targets.

In this study, two patients with severe alopecia areata who did not respond well to oral tofacitinib showed more than 50% hair regrowth after a single dose of intramuscular triamcinolone acetonide.

This study found that the novel IPC analog SIG-1451 may inhibit inflammatory cytokine release in cell-based assays relevant to allergic dermatitis.

This study observed an association between body mass index and androgenetic alopecia, with the highest prevalence occurring in individuals with a normal BMI at 34.8%.

This study found that polyamine levels in hair samples differ between androgenic alopecia and alopecia areata, suggesting potential non-invasive biomarkers to distinguish between these hair loss conditions.

In laboratory tests and mouse models, this study found that the novel IPC analog SIG-1451 may offer potent anti-inflammatory effects for treating allergic skin inflammation, potentially outperforming some current therapies in specific inflammatory phases.